tiprankstipranks
Advertisement
Advertisement
Disc Medicine Buy Rating Reiterated as APOLLO Phase III Progress and Bitopertin Outlook Support Unchanged $100 Price Target
PremiumRatingsDisc Medicine Buy Rating Reiterated as APOLLO Phase III Progress and Bitopertin Outlook Support Unchanged $100 Price Target
3M ago
Disc Medicine: Outperform Rating Reiterated as Advancing Rare-Hematology Pipeline Supports Unchanged $100 Price Target
Premium
Ratings
Disc Medicine: Outperform Rating Reiterated as Advancing Rare-Hematology Pipeline Supports Unchanged $100 Price Target
3M ago
Disc Medicine presents updated data from RALLY-MF trial at ASCO
Premium
The Fly
Disc Medicine presents updated data from RALLY-MF trial at ASCO
3M ago
Disc Medicine completes enrollment in APOLLO trial
PremiumThe FlyDisc Medicine completes enrollment in APOLLO trial
5M ago
FDA review process for accelerated approval narrows, less predictable, WSJ says
Premium
The Fly
FDA review process for accelerated approval narrows, less predictable, WSJ says
6M ago
Disc Medicine price target raised to $79 from $78 at Wells Fargo
Premium
The Fly
Disc Medicine price target raised to $79 from $78 at Wells Fargo
6M ago
Disc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks
PremiumRatingsDisc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks
6M ago
Disc Medicine reports FY25 EPS ($6.01) vs ($3.96) last year
Premium
The Fly
Disc Medicine reports FY25 EPS ($6.01) vs ($3.96) last year
6M ago
Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients
Premium
Company Announcements
Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100